What are the options for an early-stage medical device company to secure funding for their innovation? Do you know some of the routes and funding streams, including traditional venture capital, that might be a fit for your company? Johnson & Johnson Innovation, JLABS (JLABS) wants to introduce you to some of the options when it comes to funding your device, in the hopes that you meet your match and seal the deal.
This event will dive into some of the following questions:
- What alternate funding options are out there?
- How does angel money and SBIR money differ from traditional VC funding?
- What do you need to know before exploring these alternate streams?
- What is Johnson & Johnson Innovation doing in the medical device space?
John Conley | Member, Launchpad Ventures read bio»
Ram May-Ron | Managing Partner, The FreeMind Group read bio»
Rick Jones | Director, Broadview Ventures read bio»
Renee Masi | Managing Director, BioStar Ventures read bio»
[moderator] V. Kadir Kadhiresan | VP, Venture Investments, Johnson & Johnson Innovation - JJDC read bio»
10:00 AM | Registration Opens, Networking
10:30 AM | Investor Panel Discussion
11:30 AM | Q&A
12:00 PM | Networking Lunch
12:30 PM | Program Close
FREE | M2D2 Residents
$10 | General Public
$20 | At the door
110 Canal Street
Lowell, MA 01852
John Conley | Member, Launchpad Ventures
John Conley co-founded Gilliam Capital LLC, a life science investment firm, and is a member of Launchpad Venture Group in Boston. He is a board member for three healthcare startups and works with a variety of social enterprises. He is currently the Chief Operating Officer of Entrepreneurship For All, a nonprofit that is accelerating economic and social impact through fostering entrepreneurship in mid-sized cities. He was a co-founder of the RNA interference therapeutics company Alnylam Pharmaceuticals where he held the position of Vice President, Strategy and Finance and CFO through to its successful 2004 IPO. He was Vice President of Business Development at Transkaryotic Therapies through to its acquisition by Shire Pharmaceuticals. Over ten years at Biogen he served in several marketing, business development, sales and finance positions, including Country Manager - United Kingdom and Ireland, and Treasurer. He was a Manager at the strategy-consulting firm of Bain & Company. Mr. Conley graduated with a BS in Economics from the University of Pennsylvania's Wharton School and an MBA from the Yale School of Management. He was a 2014 Fellow in the Advanced Leadership Initiative at Harvard University.
Connect with John:
Ram May-Ron | Managing Partner, The FreeMind Group
For over a decade, Ram May-Ron has been a leading figure within FreeMind. Initially leading FreeMind's Professional Services Department and later becoming a partner and taking upon himself the full responsibilities of both FreeMind's marketing and business development efforts, as well as the overall management of FreeMind's professional services activities. Mr. May-Ron has more than 15 years of experience as a leading strategic analyst, both in the business and political sectors. He has led a strategic consulting firm and has served as a top strategy adviser to several international organizations and elected political officials. Mr. May-Ron serves on the board of directors for several companies and has a wide range of experience in marketing and business development. Mr. May-Ron holds an MEI (Master of Entrepreneurship and Innovation, International Business Management) from Australia's Swinburne University of Technology. He also holds a Master's degree in International Relations, focusing on strategic decision making processes from the Hebrew University of Jerusalem, winning the International Relations Department's academic excellence scholarship.
Connect with Ram:
Rick Jones | Director, Broadview Ventures
Frederick “Rick” Jones, MD, shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement. Prior to joining Broadview Ventures, Rick founded Spordiff Therapeutics, which is developing a small molecule to prevent C. difficile infection. Previously, Rick was CEO of Anchor Therapeutics, a venture-backed company developing a platform of lipidated peptides targeting intractable GPCR targets. Before that Rick held increasingly responsible positions as a general manager, business development professional and medical affairs officer with Devgen, BioRexis and Wyeth Pharmaceuticals. Early in his career, Dr. Jones practiced internal medicine, most recently as Assistant Professor in the University of Pennsylvania health system. Rick earned his undergraduate, medical and MBA degrees from the University of Pennsylvania. Rick currently serves as Board Observer or Director for Aggamin, Aria CV, Ischemia Care, Remedy, and ZZ Biotech.
Connect with Rick:
Renee Masi | Managing Director, BioStar Ventures
Renee Masi has more than 25 years of experience in the venture capital industry where she focused most recently on life science investing. Ms. Masi currently serves on the boards of Autonomix, CardiacMD, and SynergEyes. Prior to joining BioStar Ventures, Ms. Masi was a Partner with Windward Ventures, a firm focused on southern California early-stage companies, where she was responsible for the firm’s life science investing strategy. Ms. Masi was an advisor to Ventures Medical, a seed stage fund affiliated with the Texas Medical Center. In 1990, Ms. Masi opened the Boston office for Technology Funding, a $250 million venture capital fund based in San Mateo, California. She began her career as an investment banker in the healthcare finance group of Merrill Lynch. In addition to holding a BA from Stanford University and an MBA from The Wharton School of Business, Ms. Masi is also a member of the Board of Councilors for the USC Graduate School of Social Work.
Connect with Renee:
[moderator] V. Kadir Kadhiresan, Ph.D. | Vice President, Venture Investments, Johnson & Johnson Innovation - JJDC
V. Kadir Kadhiresan, Ph.D. joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2007. He serves on the boards of JJDC portfolio companies and is based in Boston, Massachusetts. Dr. Kadhiresan has more than a decade of operational experience in various functional roles including research, product development, and business development. Before joining JJDC, as head of Business Development at Guidant, Inc., now Boston Scientific, Inc., Dr. Kadhiresan led several transactions to access novel medical device technologies with venture investments, M&As, licensing and joint ventures. Prior to entering business development, he led the research and development of multiple early-stage technologies and products in cardiac rhythm management and heart failure. Dr. Kadhiresan was instrumental in the development of the cardiac resynchronization therapy for heart failure, now a multi-billion dollar market,worldwide. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation and raised venture financing for the project. In addition, Dr. Kadhiresan is an inventor on more than 40 patents and has published several articles in peer-reviewed journals. Dr. Kadhiresan received a Ph.D. and Master of Science in Biomedical Engineering from the University of Michigan, Ann Arbor, a Master of Business Administration from the Kellogg School of Management at Northwestern University, and a Bachelor of Science in Electrical Engineering from National Institute of Technology (REC), Trichy, India.
Connect with V. Kadir:
When & Where
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.